提高患者参与临床试验的系统级改革。

IF 4.7 3区 医学 Q1 ONCOLOGY
Nicole E Caston, Luqin Deng, Courtney P Williams, Emily B Levitan, Andres Azuero, Russell Griffin, Karen L Smith, Antonio C Wolff, Michelle E Melisko, Eileen H Shinn, Kathleen Gallagher, Rebekah Angove, Stephanie B Wheeler, Gabrielle B Rocque
{"title":"提高患者参与临床试验的系统级改革。","authors":"Nicole E Caston, Luqin Deng, Courtney P Williams, Emily B Levitan, Andres Azuero, Russell Griffin, Karen L Smith, Antonio C Wolff, Michelle E Melisko, Eileen H Shinn, Kathleen Gallagher, Rebekah Angove, Stephanie B Wheeler, Gabrielle B Rocque","doi":"10.1200/OP-24-00736","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Over the course of the COVID-19 pandemic, the Food and Drug Administration allowed cancer clinical trials to make modifications. As policymakers consider sustaining these modifications, understanding patient perspectives on impact is critical.</p><p><strong>Methods: </strong>This cross-sectional study used survey data collected between August 2021 and September 2021 by the Translational Breast Cancer Research Consortium and December 2022 by Patient Advocate Foundation among female breast cancer survivors. Respondents reported how changes to location, telemedicine, convenience, and opting out of certain procedures would affect their willingness to participate in a trial. Respondents' county-level vulnerability was determined using five-digit Federal Information Processing Standard codes to link to the Social Vulnerability Index (SVI) overall theme (range, 0-1). According to the SVI, the most vulnerable counties are those in the upper 10% of the overall theme. Model-estimated odds ratios (ORs) and 95% CIs were estimated using multinomial logistic regression models to explore the association between county-level social vulnerability and willingness to participate.</p><p><strong>Results: </strong>Overall, 573 women were included, 12% lived in the most vulnerable counties, and 18% had previous trial participation. Over half (53%) reported that they would be very willing to participate in a trial that offered medication delivery to the home. When compared with all other counties, respondents in most vulnerable counties did not have increased willingness to participate in a trial using telemedicine (OR, 0.21 [95% CI, 0.07 to 0.63]). Results were similar for all other trial modifications, though not statistically significant.</p><p><strong>Conclusion: </strong>Our sample of breast cancer survivors viewed trial modifications favorably. However, respondents in the most vulnerable counties were less likely to be influenced by these modifications. Research is needed to understand if additional modifications would influence participation of this vulnerable population.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400736"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"System-Level Transformations to Increase Patient Participation in Clinical Trials.\",\"authors\":\"Nicole E Caston, Luqin Deng, Courtney P Williams, Emily B Levitan, Andres Azuero, Russell Griffin, Karen L Smith, Antonio C Wolff, Michelle E Melisko, Eileen H Shinn, Kathleen Gallagher, Rebekah Angove, Stephanie B Wheeler, Gabrielle B Rocque\",\"doi\":\"10.1200/OP-24-00736\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Over the course of the COVID-19 pandemic, the Food and Drug Administration allowed cancer clinical trials to make modifications. As policymakers consider sustaining these modifications, understanding patient perspectives on impact is critical.</p><p><strong>Methods: </strong>This cross-sectional study used survey data collected between August 2021 and September 2021 by the Translational Breast Cancer Research Consortium and December 2022 by Patient Advocate Foundation among female breast cancer survivors. Respondents reported how changes to location, telemedicine, convenience, and opting out of certain procedures would affect their willingness to participate in a trial. Respondents' county-level vulnerability was determined using five-digit Federal Information Processing Standard codes to link to the Social Vulnerability Index (SVI) overall theme (range, 0-1). According to the SVI, the most vulnerable counties are those in the upper 10% of the overall theme. Model-estimated odds ratios (ORs) and 95% CIs were estimated using multinomial logistic regression models to explore the association between county-level social vulnerability and willingness to participate.</p><p><strong>Results: </strong>Overall, 573 women were included, 12% lived in the most vulnerable counties, and 18% had previous trial participation. Over half (53%) reported that they would be very willing to participate in a trial that offered medication delivery to the home. When compared with all other counties, respondents in most vulnerable counties did not have increased willingness to participate in a trial using telemedicine (OR, 0.21 [95% CI, 0.07 to 0.63]). Results were similar for all other trial modifications, though not statistically significant.</p><p><strong>Conclusion: </strong>Our sample of breast cancer survivors viewed trial modifications favorably. However, respondents in the most vulnerable counties were less likely to be influenced by these modifications. Research is needed to understand if additional modifications would influence participation of this vulnerable population.</p>\",\"PeriodicalId\":14612,\"journal\":{\"name\":\"JCO oncology practice\",\"volume\":\" \",\"pages\":\"OP2400736\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO oncology practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/OP-24-00736\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO oncology practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/OP-24-00736","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:在COVID-19大流行期间,美国食品和药物管理局允许癌症临床试验进行修改。当政策制定者考虑维持这些修改时,了解患者对影响的看法至关重要。方法:本横断面研究使用由转化乳腺癌研究联盟于2021年8月至2021年9月和患者倡导基金会于2022年12月在女性乳腺癌幸存者中收集的调查数据。受访者报告了地点、远程医疗、便利性和选择退出某些程序的变化如何影响他们参与试验的意愿。受访者的县级脆弱性是使用五位数的联邦信息处理标准代码与社会脆弱性指数(SVI)总体主题(范围,0-1)相关联来确定的。根据SVI,最脆弱的国家是那些在整体主题中排名前10%的国家。采用多项logistic回归模型估计模型估计比值比(or)和95% ci,探讨县级社会脆弱性与参与意愿之间的关系。结果:总共纳入573名妇女,其中12%生活在最脆弱的县,18%以前参加过试验。超过一半(53%)的人报告说,他们非常愿意参加一项提供药物递送到家中的试验。与所有其他县相比,大多数脆弱县的受访者并没有增加参与远程医疗试验的意愿(OR, 0.21 [95% CI, 0.07至0.63])。所有其他试验修改的结果相似,但没有统计学意义。结论:我们的乳腺癌幸存者样本对试验修改持积极态度。然而,最脆弱县的答复者不太可能受到这些修改的影响。需要进行研究,以了解额外的修改是否会影响这一弱势群体的参与。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
System-Level Transformations to Increase Patient Participation in Clinical Trials.

Purpose: Over the course of the COVID-19 pandemic, the Food and Drug Administration allowed cancer clinical trials to make modifications. As policymakers consider sustaining these modifications, understanding patient perspectives on impact is critical.

Methods: This cross-sectional study used survey data collected between August 2021 and September 2021 by the Translational Breast Cancer Research Consortium and December 2022 by Patient Advocate Foundation among female breast cancer survivors. Respondents reported how changes to location, telemedicine, convenience, and opting out of certain procedures would affect their willingness to participate in a trial. Respondents' county-level vulnerability was determined using five-digit Federal Information Processing Standard codes to link to the Social Vulnerability Index (SVI) overall theme (range, 0-1). According to the SVI, the most vulnerable counties are those in the upper 10% of the overall theme. Model-estimated odds ratios (ORs) and 95% CIs were estimated using multinomial logistic regression models to explore the association between county-level social vulnerability and willingness to participate.

Results: Overall, 573 women were included, 12% lived in the most vulnerable counties, and 18% had previous trial participation. Over half (53%) reported that they would be very willing to participate in a trial that offered medication delivery to the home. When compared with all other counties, respondents in most vulnerable counties did not have increased willingness to participate in a trial using telemedicine (OR, 0.21 [95% CI, 0.07 to 0.63]). Results were similar for all other trial modifications, though not statistically significant.

Conclusion: Our sample of breast cancer survivors viewed trial modifications favorably. However, respondents in the most vulnerable counties were less likely to be influenced by these modifications. Research is needed to understand if additional modifications would influence participation of this vulnerable population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.40
自引率
7.50%
发文量
518
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信